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Objectives: Legal analysis can highlight important issues that are relevant when deciding whether a medical technology should be implemented or reimbursed. Literature and studies
show that even though the law is an acknowledged part of health technology assessment (HTA), legal issues are rarely considered in practice. One reason for this may be the lack of
knowledge about the diversity of legal issues that are relevant for HTA. Therefore, this contribution aims primarily to identify and then explain the relevant legal issues in HTA. This
study offers a framework for identifying the legal issues in HTAs in different jurisdictions and provides a basis for further research.
Methods: After extensive literature search, the authors review Swiss health law to identify legal issues that are relevant to HTA. The authors then categorize these legal issues using
a framework with an inside and outside perspective. Finally, they explain a selection of these legal issues with several examples.
Results: This study reveals numerous legal issues that are relevant for HTA and underlines the necessity of incorporating legal analysis in HTAs. The suggested perspectival framework
in this study provides a basis to structure the legal analysis. The identified legal issues are relevant in other countries and the perspectival framework is transferable to other
jurisdictions.
Conclusions: The article underlines the importance of in-depth discussion about the role of law in HTA. It provides a structured overview of the legal issues in HTA and suggests a
development of more concrete instruments toward a standardized legal technology assessment.
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If HTA is not integrated into a country’s legal framework, it
cannot yield its full potential. For instance, if the process of a
reimbursement decision is not in accordance with the theory
of HTA—including interdisciplinarity, independency, scientific
methods, or transparency—the legally prescribed process may
lead to biased reimbursement decisions.
At the same time, HTA and the coverage decision-making
process is interpenetrated by law. The assessment and appraisal
of HTA must address several legal issues—to a larger degree
than previously described (1;2). It does not suffices to rush
through a legal assessment by simply identifying the impor-
tance of informed consent. Informed consent is an important
legal issue, but there are several other important legal issues
influencing the daily use of health technologies.
HTA is defined as an interdisciplinary process and many
international definitions consider the legal discipline as one part
of it. If those definitions are taken seriously, our understanding
of the legal analysis of HTA must improve (3). This article
provides a structured introduction to the legal issues of HTA.
Because health law operates mainly on a domestic basis, we
will look exclusively at Swiss law. However, the legal issues in
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Swiss law are relevant in other countries, even if the application
of the specific national law (and its outcomes) may vary.
METHOD
The authors carried out a literature review in national and inter-
national databases to identify publications that focus on the legal
analysis of HTA (i.e., PubMed, World Cat, Swisslex). Only four
relevant publications could be found (1–4). Due the small num-
ber of publications in this field, the authors then looked at Swiss
laws governing the issues relevant to HTA by using a qualitative
approach. The findings of this analysis were structured into an
outside and an inside perspective framework. The authors illus-
trate the importance of these legal issues with common practical
examples drawn from the Swiss healthcare system.
TWO PERSPECTIVES
To structure the identification of the legal issues in HTA, we
suggest dividing these issues into an outside and an inside per-
spective.
The outside perspective focuses on the macro level of HTA
and includes legal questions concerning HTA as a whole. Ex-
amples for this perspective are the contractual relation between
the decision-maker and those carrying out the HTA, as well as
the legal process in which HTA is used for decision making.
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Nature of HTA as a decision-making instrument (legal 
opinion)
Collaboration between client and provider (for 
example contracts, rights and duties, liability issues)
Implementation of HTA (for example public 
investment or reimbursement decisions)
Responsibility of the decision maker (decision-making 
in public interest, jurisdiction of decisions, responsibili-
ty for wrong decisions)
Public tender for HTA mandates (fairness in public 
purchase)
Effects on the system and its stakeholders (rights and 
duties of the insurance companies, hospitals, physicians 
etc.)
International collaboration (for example EUnetHTA)
Patient (for example right and duty to decide, 
obligation to collaborate with care supplier)
Care Provider (for example rights and duties, lex artis 
treatment, further qualifications, responsibilities)
Technology (for example patent, market entry, 
off-label use, orphan drugs, data protection, clinical 
trials, product liability)
Financing (for example efficacy, effectiveness, equity, 
human dignity, constitutional duty to take 
complementary medicine into account)
Methodology (are the methods which are used for 
HTA lawful? For example, would the use of QALYs or a 
discriminating outcome/parameter be illegal?)
Outside Perspective
„Macro level“
Inside Perspective
„Micro level“
Figure 1. Legal issues in HTA:Outside and Inside perspective.
The inside perspective, by contrast, focuses on the micro
level of HTA. It includes legal issues within the elaboration
process of an HTA report. For example, there are legal criteria
forwhether currentmedical and economical evidence fulfills the
legal requirements to allow for the approval for reimbursement
of certain technology. To identify the crucial legal issues, it is
desirable to divide issues belonging to the inside perspective
into five sub-categories (Figure 1).
Outside Perspective Issues
Nature and Collaboration. For lawyers it is essential to understand the
legal characteristics of HTA and an understanding of HTA’s
legal nature provides a basis for identifying its risks and bur-
dens. Assessing the characteristics of HTA seems to be simi-
lar to an existing legal instrument: the legal opinion. A legal
opinion is written expertise about a certain topic. It
provides specific, mostly science based information about an
individual case or a narrowed research question (5). The sim-
ilarities between HTAs and legal opinions makes it possible
to apply the existing legal framework on opinions to HTA
reports.
First, an HTA report requires collaboration between a client
and its provider, for example, between a health authority and
the HTA producer. Details of such collaborations are often
(and hopefully) settled in a written contract, the validity of
which depends on its accordance with the law. For HTA re-
ports, there are two types of contracts to consider: the con-
tract for work and services and the simple agency contract
(6).
The value of the contract for work and services is its mea-
surable result and guaranteed outcome. The outcome (“the ser-
vice”) is characterized by a structured, precise and predefined
production process that is typical of systematic reviews. Con-
sequently, the HTA producer becomes liable for the accuracy of
the outcome of a systematic review.
Example: If there is a methodological error in the report
that ultimately leads to a wrong decision, theHTA producermay
become responsible for the damages he caused. The contract
for work and services also obligates the customer to inspect
the work for defects and inform the contracting party of any
defects, otherwise the co-contractor cannot be held liable for
any complaints in this regard.
Thus, within this basic contractual framework, the HTA
producer would be liable for the result of the systematic review
and his or her client is often obliged to inspect the report for
methodological defects and biases (7). Because the decision-
maker is not usually well grounded in HTA methodology, it
would be important to extend the contract to increase the pro-
tection of the customer by including an external review process
or adding an explicit guarantee.
Instead of focusing on the outcome, the simple agency con-
tract highlights the diligent and faithful performance of the
business, which means that a specific result cannot be expected
because of the nature of the work (8). Taking this into account,
an HTA report may be considered under the law of a simple
agency contract if the result is unpredictable and may differ
depending on the expert’s interpretation such as the ethical or
legal appraisal of clinical and economical evidence. In this case,
an HTA producer (whether it is an individual or an organiza-
tion) is liable for the diligent and faithful performance of the
appraisal. Within this contract type, the client has no obligation
to examine the HTA report for defects or biases and, in contrast
to the contract for work and services, the customer can fully
rely on the report and sue the provider for damages, as soon as
an error in the report is noticed.
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Assignment
Assessment
Appraisal
Decision
Collaboration ends by delivering the 
HTA report. However, rights and 
duties continue.
Collaboration starts by concluding a 
contract
Simple agency contract:
a.  Focus on faithful and diligent                                                                                                
iii  performance
b.  No duty of the customer to inspect 
iiiiithe report
c.  Liability of HTA doer measured on 
iiiiprofessional standards
Contract for work and services:
a.  Focus on the outcome
b.  Customer obliged to                                            
iiii inspect the HTA report for defects i  i 
iiii and biases
c.  Maybe additional protection for 
iijjiicustomer needed (i.e. external 
iijjiireview or guarantee)
Contract Element 1
- Limited liability for outcome
- Duty of the client to inspect the 
iiproduct
Contract Element 2
Liability for performance
Figure 2. Contract elements of HTA collaboration.
An analysis of these two contract types shows that HTA
collaboration contains (a) different contract types, which cre-
ate (b) different rights and duties for the collaborators. For the
assessment-process, the contract for works and services is appli-
cable. Because of the contractual framework, it may be helpful
to increase the protection of the decision-maker by including an
external review or a guarantee to the contract. For the appraisal
process, the simple agency contract is applicable and it relieves
the decision-maker of the duty to investigate the HTA report for
defects and biases and obliges the HTA producer to conduct the
HTA according to the professional standards (Figure 2).
Because HTA reports can be described as legal opinions,
the legal requirements of opinions are consequently applicable
to HTA reports as well. For example, if a patient does not agree
with a specific reimbursement decision (based on HTA), he has
the right to file suit. If the patient is able to present convincing
evidence to prove the faultiness of the HTA report, the judge
may rule in favor of the plaintiff and the insurance company
would be forced to reimburse the treatment. The verdict may
also have consequences on the HTA producer, if the decision-
maker decides to file a liability claim because of malpractice.
Thus, there are not only scientific guidelines but also legal con-
siderations that an HTA report must follow. As it happens, the
scientific guidelines considerably overlap with the expectations
of a court such as concerns about conflict of interest, scien-
tific guidelines, etc. (9–11). However, the HTA producer has
to ensure that his or her work fulfills these minimal scientific
requirements to limit liability.
Implementation
The question of successful implementation of an HTA report
highly depends on its external legal framework—or in other
words: if regulation is poor, the impact of HTA will be low as
well.
Switzerland currently pursues a pragmatic process of re-
imbursement decision making. To be reimbursed, a technology
must fulfill three criteria; the technology must be effective, ap-
propriate, and economical (12). If, for example, a technology
producer believes that a technology fulfills those criteria, the
producer can initiate an administrative process to ask for reim-
bursement. The applicant is responsible for producing the sci-
entific evidence by filling out an official application form (13).
The application will be reviewed by the Swiss Federal Office of
Public Health and then forwarded to a stakeholders’ commit-
tee, which makes a recommendation to the decision-maker. If
sufficient scientific evidence is provided, the technology may be
covered by health insurance (12–14).
A comparison of the Swiss approach with the typical HTA
process reveals the following differences (Figures 3 and 4):
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Decision
Coverage decision on behalf of the                
HTA report
Assignment
Selection of the research question, 
prioritizing, ordering HTA-report
Assessment
Elaboration of the current state of    
science (interdisciplinary)
Appraisal
Reflection and discussion about the 
assessed evidence (interdisciplinary)
Recommendation
Prepare a recommendation to the 
decision-maker, file the HTA report
Sphere: Decision-maker
Sphere: Science
Support by HTA producer to choose
and shape a research question
Reevaluation of the decision, need for 
updating the evidence
Figure 3. Typical HTA Decision Making Process.
Sphere: Stakeholder
No systematic reevaluation 
Sphere: Decision-maker
Sphere: Science
Assessment
Elaboration of current 
state of science by 
(private) applicant 
(danger of conflict of 
interest)
Decision
Final reimbursement decision 
on the basis of the 
commission‘s report
Assignment
(Private) party initiates 
decision making process
Appraisal & Recommendation
Reflection and discussion about the 
assessed evidence, Stakeholder 
Committee
Review SFOPH
Review of the application, 
obtaining expert opinions
Expert
Elaboration of technology 
specific expert opinions
Figure 4. Swiss Reimbursement Decision Making Process (Medical Services).
The two figures show obvious differences between the typ-
ical and the Swiss reimbursement decision process. The ad-
vantage of the Swiss process may be its pragmatic, liberal and
integrative approach, because everyone is allowed to initiate
such a reimbursement decision process. The approach may also
be cheaper for the state, because the time-consuming collection
of scientific evidence must be prepared by the applicant. How-
ever, the weaknesses of the Swiss approach are its potential for
severe conflict of interest, biased assessments, and stakeholder
influenced appraisals.
The success of an HTA significantly depends on the appli-
cable domestic law where it is prepared. Consequently, the legal
framework must be organized in such a way that the results of
unbiased HTA reports can impact the health system.
Responsibility of the Decision Maker
Even if the discretionary powers of the appraisal committee and
the decision-makers sometimes seem to be limitless, the deci-
sionmakers are certainly not allowed tomake randomdecisions.
INTL. J. OF TECHNOLOGY ASSESSMENT IN HEALTH CARE 30:6, 2014 590
https://doi.org/10.1017/S0266462314000683
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 30 May 2017 at 17:07:45, subject to the Cambridge Core terms of use, available at https:/www.cambridge.org/core/terms.
Framework for identifying legal issues in HTA
A government, committee or private person, working in public
service, is legally bound to work and decide in the society’s best
interest. For instance, the Swiss Constitution requires everyone
who is participating in state activities to uphold the fundamental
rights of the Constitution (15).
Taking these duties into account, the legal nature ofHTAcan
strengthen the government’s commitment to follow the evidence
of an HTA report as well. Looking at the long-term practice of
the Swiss Social Insurance Authorities (which works frequently
with legal opinions), we observe that the authorities usually fol-
low expert opinions, as long as they are reasonable and of good
quality. Furthermore, the Swiss Federal Court usually requires
in its traditional case law, that the courts follow an expert’s
opinion. If a court wishes to disregard an expert opinion, it
must give plausible reasons and additional justification for the
refusal (9). There are good reasons to implement this process for
reimbursement decision making: if an HTA report fulfills the
scientific standards and contains obvious evidence, a decision-
maker should generally be required to follow the HTA report.
Public Tender
If a public HTA institution wants to appoint a company to elab-
orate an HTA report, it is usually obliged to invite bidders to
apply for a public order—legally known as public tender. The
tender process is intended to make the public purchase more
transparent, fair and cheaper. If the institution is private, this
duty is not obligatory, as long as it is not indirectly funded by
public money (16).
Example: The Swiss Medical Board (SMB) produces HTA
reports in collaboration with private companies. Even though
the organization is based on civil law (because it is an asso-
ciation), the SMB is obliged to undertake a tender, because of
its public funding. Therefore, the SMB’s decision to collaborate
with an HTA producer must to be based on measurable criteria.
Furthermore, unsuccessful applicants have the right to appeal
against this decision.
Effects of the Decision on the Health System and Its Stakeholders
Once the reimbursement decision is made, the legal frame-
work should require that all stakeholders respect the decision.
In Switzerland, for example, the law prescribes which medical
services must be covered by the insurance companies. An insur-
ance companywill be sanctioned, if it disregards a governmental
reimbursement decision (12). Medical doctors are bound to the
decision as well (8;12).
Thus, the legal framework should ensure successful imple-
mentation of health technologies by making the reimbursement
decision mandatory for all involved stakeholders.
International Collaboration
There are often similar HTAprojects across domestic borders. If
HTAs are generally binding, it could be the law aswell, which in-
creases international collaboration, bymaking it generally bind-
ing (17). International collaboration in HTA has great potential,
but also without mandatory agreements international collabora-
tion inHTA seems already on a promising track. Projects such as
the HTAi Association and EUnetHTA are examples of interna-
tional cooperation and exchange—without legal enforcement.
Inside Perspective Issues. Because the legal assessment of a technology
can be enormously complex and extend into several legal sub-
areas, it is helpful to divide the legal technology assessment
into a few categories. Therefore, we choose a slightly different
approach from EUnetHTA (4) and suggest the following five
categories: (a) Patient, (b) Care Provider, (c) Technology, (d)
Financing, and (e) Methodology.
Patient
The category of the patient focuses on every legal issue that may
affect the patient. Here we consider any possible situation that
could cause discomfort or harm to the patient—before, during,
and after the treatment.
The most important issue within this category is the pa-
tient’s consent to the treatment. This right to give consent to a
treatment is nonnegotiable (15;18). To be able to give consent,
the patient has to be informed about the entire treatment-path
and its potential risks. If there are doubts about the patient’s
ability to consent, the care providers may have to involve the
patient’s relatives or the guardianship authority in the treatment
decision to decide in the patient’s best interest (8).
Example: For a surgical brain tumor intervention, it may
be helpful to consult the statistics and determine, if patients
with brain tumor frequently show cognitive disabilities, which
are difficult for the doctor to identify. It then might be helpful
to recommend in the HTA report that the consent should be
additionally confirmed by the relatives, a decision board and/or
by a psychiatrist, to eliminate remaining uncertainties. Perhaps
the HTA report could also refer to specific forms and checklists
that could increase the validity of the informed consent.
The patient’s category also includes the patient’s duty to
pay for the treatment (8). Even if many medical treatments are
reimbursed by health insurance, there may still be treatments
that have to be paid for out-of-pocket. As a result, the patient is
incentivized to consider cheaper alternatives or to find outwhich
criteria have to be fulfilled to qualify for full reimbursement.
Example: A (patient-centered) HTA report could refer to
promising alternative treatment methods and outline detailed
criteria under which (legal) circumstances a reimbursement is
possible.
Furthermore, the patient is obliged to participate in the
treatment process. If the patient impedes the medical service,
he or she will be made responsible for the consequences. It can
be assumed that the more a treatment demands a patient’s par-
ticipation (for example through the collection of information,
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assessing pain, etc.), the more the treatment’s success becomes
the patient’s responsibility.
Example 1: A patient is legally obliged to inform the doctor
about his HIV infection.
Example 2: The HTA report could strengthen patient’s
responsibility by listing the patient’s specific duties. This
would result in reducing the physician’s liability where ap-
propriate and increasing the patient’s commitment to the
treatment.
Care Provider
The category of Care Provider focuses on legal issues where
the technology is somehow related with care. The most impor-
tant care-related laws are those that set out the duties created by
patient-care provider relationship. Due to the number of pos-
sible legal issues within this category, only two issues will be
discussed in depth.
The physician’s main obligation is to provide the best pos-
sible treatment to the patient. If the doctor chooses an inappro-
priate or outdated treatment, he could become liable when the
patient is harmed or does not recover (8).
Example: A recent HTA report from Switzerland pointed
out that in the case of Anterior Cruciate Ligament (ACL) in-
jury there is no persuasive evidence to indicate reconstructive
surgery as a first step. According to the report, the conservative
treatment of physiotherapy without surgery should be applied,
except for cases where the patient has significant pressure on
his or her knee (for example sport athletes, construction work-
ers, etc.). If an ACL patient is treated with immediate surgery
and, during the surgery, experiences an ordinary complication,
the surgeon may become liable, because he did not consider the
HTA’s recommendation (19).
Furthermore, the doctor has to inform his patient about the
treatment. The duty to inform includes a detailed explanation of
the diagnosis, an outline of alternative treatments, reasons why
the proposed treatment is the most appropriate, and specific
information about the financial aspects of the treatment. If the
physician cannot prove that he has fully informed his patient (for
example by documenting the conversation[s] with the patient),
the physician might be charged with assault and/or be liable for
any damages associated with the treatment (8).
Example: Referring to the latest scientific knowledge, an
HTA report usually points out why and under which condi-
tions a certain health technology should be applied—or not.
The information from an HTA report could be used by physi-
cians to minimize the asymmetry of knowledge between them
and their patients. The report could suggest an up-to-date
checklist as well, which includes every crucial point of a tech-
nology and, thus, professionalizes the information flow be-
tween physicians and patients. The patient would be informed
in more detail and the physician would reduce his or her
liability.
Technology
The category of Technology focuses on any legal issue related to
the technology itself. Every step in the life cycle of a technology
needs to be legally assessed.
The most important technology-related legal issues are
medical technologies (20;21), research with humans, data pro-
tection issues or patent law. Furthermore, there is product lia-
bility and, perhaps, issues related to the constitutional right of
economic freedom. Again, only a few of those issues will be
discussed more closely.
Data protection is a significant issue in medicine. Not only
the physician, but also the developers of medical technologies
are obliged to save and to protect data against unauthorized third
parties. The Swiss data protection law considers patient related
data as particularly vulnerable. For these reasons, data must be
collected carefully and stored safely (22).
Example: Technology developers and users have to ensure
that the screening machine protects collected data safely. An
HTA report should indicate how a technology could conflict with
the law of data protection and raise awareness for those issues.
The challenges of personalized medicine will, in particular,
increase expectations on this matter.
Patent law may also be an issue for conducting an HTA re-
port. For various kinds of intellectual property there are not
only national, but also international laws to consider. Pro-
tected patents are usually registered in national and international
databases. The protection for these patents usually lasts for 20
years (23).
Example: In the prioritization of a technology, the length
of available patent protection ought to be considered. For in-
stance, if the patent of a medical drug will expire soon, it would
not necessarily make sense to conduct the HTA, because there is
significant expected price competition. Alternatively, anHTA re-
port may contain a reference that the patent of a technology will
expire soon and, thus, invite other producers to enter/prepare
for the competition.
Financing
The category of Financing considers all legal issues around the
technology that could or should have an impact on the decision-
maker.
The most important legal issues within the financial cate-
gory are the criteria of health insurance law for a valid reim-
bursement decision. Furthermore, the decision has to be in ac-
cordance with the constitution and respect human rights such as
equality, human dignity, personal freedom, etc. (15;18). These
issues are examined more closely below.
According to Swiss health insurance law, a positive reim-
bursement decision requires three criteria. A technology needs
to be effective, appropriate, and economical. A technology is
effective if it causes a measurable benefit to the patient. The
technology is appropriate if it objectively is the best option
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in the individual case. Finally, the treatment is considered as
economical as long as there is no cheaper treatment alternative
(24).
Example: An HTA report would need to consider those
criteria carefully. They would also need to consider the lat-
est case law and compare the assessed technology with other
reimbursement decisions. These legal considerations are prob-
ably the most essential ones for the decision-maker, because its
decision is strictly bound by these criteria.
Furthermore, the reimbursement decision has to be in ac-
cordance with the Swiss Constitution. Every technology has to
be assessed to whether it has an impact on constitutional human
rights, such as human dignity, personal freedom, or equality
(15;18).
Example 1: Recently, the Swiss Federal Court decided in the
so-called Myozyme Case (25) that the economical criterion is
disproportionate and violates the constitutional right of equality
because the effectiveness of the treatment was too low and the
treatment costs too high. Therefore, the court set a rough thresh-
old: more than 100,000 Swiss Francs per gained life year would
be considered disproportionate and thus unconstitutional.
Example 2: The obligatory health insurance reimburses la-
paroscopic obesity surgery for peoplewith a BMI over 35 (under
further conditions). This surgery usually causes a significant
weight reduction. The consequences might be disfiguring skin
folds, which can often cause psychological problems. For this
reason, a reimbursement decision to deny plastic surgery (to
remove the remaining skin) might be considered a violation of
human dignity. Thus, legal consequences such as the violation
of human dignity should be assessed in an HTA report as well.
Methodology
Finally, there is a slightly different category that is indirectly
part of HTA as well: the category of methodology. Because
most HTAs are run by a strict methodological handbook, it
is helpful to assess the entire handbook to identify potential
conflicts with the law.
Example: The use of QALYs is controversial, because they
may systematically discriminate against people with difficul-
ties and disabilities. Therefore, the effects of QALYs need to be
assessed to determine under which circumstances the discrimi-
nation becomes legally relevant.
CONCLUSION
This short introduction into the legal issues of HTA underlines
the presence of several legal issues relevant for HTA produc-
ers as well as the technology assessment itself. Looking at the
potential risks for all HTA stakeholders, it seems vital to con-
sider the legal issues in HTA before a legal dispute occurs. As
illustrated, the harm and the consequences can be serious.
The suggested perspectival framework can be used in other
jurisdictions, although the specific regulation may vary from
country to country. The framework makes it easier to under-
stand the various legal issues of HTA and provides a scientific
basis for further research toward a sustainable legal technology
assessment.
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